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Abstract 
Background: Trauma focused cognitive behavioral therapy (Tf-CBT) and eye movement 
desensitization and reprocessing (EMDR) are two highly effective treatment options for post-
traumatic stress disorder (PTSD). Yet, on an individual level, PTSD patients vary 
substantially in treatment response. The aim of the paper is to test the application of a 
treatment selection method based on a personalized advantage index (PAI). 
Method: The study used clinical data for patients accessing treatment for PTSD in a primary 
care mental health service in the north of England. PTSD patients received either EMDR (N = 
75) or Tf-CBT (N = 242). The Patient Health Questionnaire (PHQ-9) was used as an outcome
measure for depressive symptoms associated with PTSD. Variables predicting differential 
treatment response were identified using an automated variable selection approach (genetic 
algorithm) and afterwards included in regression models, allowing the calculation of each 
patient’s personalized advantage index (PAI). 
Results: Age, employment status, gender and functional impairment were identified as 
relevant variables for Tf-CBT. For EMDR, baseline depressive symptoms as well as 
prescribed antidepressant medication were selected as predictor variables. Fifty-six percent of 
the patients (n = 125) had a PAI equal or higher than one standard deviation. From those 
patients, 62 (50%) did not receive their model-predicted treatment and could have benefited 
from a treatment assignment based on the PAI. 
Conclusions: Using a PAI-based algorithm has the potential to improve clinical decision-
making and to enhance individual patient outcomes, although further replication is necessary 
before such an approach can be implemented in prospective studies. 
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Introduction 
Within the context of evidence-based medicine, a series of clinical practice guidelines 
for post-traumatic stress disorder (PTSD) have been developed and published internationally 
(e.g. the National Institute for Health and Clinical Excellence, 2005; Foa, Keane, Friedman, 
& Cohen, 2008). In a review, Forbes and colleagues (2010) examined existing guidelines and 
concluded that trauma-focused cognitive behavioral therapy (Tf-CBT) is consistently 
recommended as first-line psychological treatment, whereas eye movement desensitization 
and reprocessing (EMDR) is not always endorsed as equivalent. Despite these differences, 
CBT as well as EMDR have been shown to be highly effective for the treatment of PTSD in 
several randomized controlled trials and systematic reviews (Benish, Imel, & Wampold, 
2008; Bisson et al., 2007; Bisson & Andrew, 2009; Bradley, Greene, Russ, Dutra, & Westen, 
2005; Ehlers et al., 2010; Seidler & Wagner, 2006; Watts et al., 2013).  
Although both interventions can be effective in the treatment of PTSD, patients with 
this condition vary substantially in their treatment response and illness course. Dropout rates 
in PTSD treatments vary between 14% and 32% (Van Minnen, Arntz, & Keijsers, 2002; 
Hembree et al., 2003; Van Etten & Taylor, 1998; Resick, Nishith, Weaver, Astin, & Feuer, 
2002; Schottenbauer, Glass, Arnkoff, Tendick, & Gray, 2008). Furthermore, several studies 
show that between 41% and 58% remain clinically distressed after treatment (Tarrier et al., 
1999; Resick et al., 2002). In a review, Schottenbauer and colleagues (2008) report non-
response rates as high as 50%. Despite research results which show equivalent outcomes on 
average for Tf-CBT and EMDR, individual patients might respond differently to each of the 
two treatments. It is possible that a treatment that is highly effective for one patient might be 
ineffective or even harmful for another patient. Based on this argument, Schnyder (2005), for 
example, suggests a need to develop new treatments for PTSD. In contrast, Seidler and 
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Wagner (2006) argue that future research should focus on understanding which patients are 
more likely to benefit from one treatment or the other.  
In this sense, clinical research is gradually shifting to an increased focus on the 
individual patient. Tailoring treatments to the specific characteristics of a patient is an 
approach that has been described as precision medicine. This approach has a long tradition in 
medicine, exemplified by attempts to identify genetic and neuroimaging markers that predict 
differential treatment response to pharmacological treatments (see for example: Hamburg & 
Collins, 2010). In the context of psychotherapy research, different strategies have been 
applied to empirically define the most promising treatment for a particular patient (e.g., 
Cuijpers, 2014; Cohen & DeRubeis, 2017; DeRubeis et al., 2014; Kessler et al., 2017; Lutz et 
al., 2006; Ng & Weisz, 2016).  
Thus far, in the context of psychotherapy research, some studies have focused on the 
task of developing prognostic and/or prescriptive models for differential treatment selection. 
A model is called prognostic if the variables included predict response in a single treatment 
whereas prescriptive variables are often referred to as moderators that affect the direction or 
strength of the differences in outcome between two or more treatment conditions (Cohen & 
DeRubeis, 2017). In this sense, DeRubeis and colleagues (2014) developed a prescriptive 
model, which they called Personalized Advantage Index (PAI). Implemented in the context of 
two highly effective treatments, the PAI predicted a clinically meaningful advantage for 60% 
of depressed patients if they had been assigned to their predicted optimal treatment. Huibers 
et al. (2015) applied the same approach to a sample where depressed patients were 
randomized to either cognitive therapy or interpersonal psychotherapy (N = 134). The PAI 
was able to predict a clinically meaningful advantage in one of the therapies for 63% of the 
sample. More recently, Delgadillo, Huey, Bennett and McMillan (2017) used data from a 
large naturalistic cohort (N = 1512) of patients to construct a prognostic index. They found 
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that a subgroup of patients referred to as “complex cases” tended to attain significantly better 
outcomes if they were initially assigned to high intensity psychotherapies, rather than low 
intensity CBT. Similarly, Kessler et al. (2017) recommended using prognostic models to 
estimate predictions for each treatment type, ideally using large naturalistic clinical samples 
to identify reliable predictors that could be applied in future clinical trials.  
In summary, the application of treatment selection based on prognostic and 
prescriptive models has mainly focused on samples of patients suffering from depression, 
where they were most often randomly assigned to different treatments. However, 
heterogeneity in treatment response is not limited to patients with major depression. As 
highlighted above, PTSD is heterogeneous in presentation and prognosis, and therefore this 
diagnosis is not in itself sufficient for making an optimal treatment decision. On this basis, 
the objective of the present study was to develop a treatment selection method using data 
from a naturalistic PTSD sample where patients were treated either with Tf-CBT or EMDR, 
in order to identify the optimal treatment for each patient.  
Methods 
This study was based on the analysis of anonymous clinical case records for N = 317 
patients accessing treatment for PTSD in a primary care mental health service in the north of 
England. This service was part of the national Improving Access to Psychological Therapies 
(IAPT) programme in England, which offers evidence-based psychological interventions 
organized in a stepped care model (Clark, 2011). Patients with PTSD received either trauma-
focused cognitive behavioral therapy (Tf-CBT; Ehlers, Clark, Hackmann, McManus, & 
Fennell, 2005) or eye-movement desensitization and reprocessing (EMDR; Shapiro, 2001). 
Following clinical guidelines (NICE, 2005), these treatment options were explained at the 
time of initial assessments and patients made joint decisions with the assessing therapists 
about their treatment of choice. In the analysis sample, 242 patients received Tf-CBT 
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whereas 75 patients received EMDR. This distribution of cases across treatments was also 
influenced by the larger number of CBT therapists (N=43) relative to EMDR therapists in 
this sample (N=4). These interventions were delivered by qualified therapists who practiced 
under regular clinical supervisions, in weekly appointments for up to 20 sessions. De-
identified clinical assessment records were available, including demographic and clinical 
information (primary diagnosis, session-to-session outcome measures) (see Table 1).  
Measures 
 Patient Health Questionnaire (PHQ-9). The PHQ-9 is a validated nine-item 
screening tool, which is routinely used in IAPT services to measure symptom improvement 
(Kroenke, Spitzer, & Williams, 2001). The questionnaire has been developed to measure 
depression. Patients rate each item on a 0 to 3 scale (0 = ’not at all’ to 3 = ‘nearly every day’), 
yielding a total score between 0 and 27. A difference of six points on the PHQ-9 was taken as 
a reliable change index (Richards & Borglin, 2011). Classification of PHQ-9 scores following 
Kroenke, Spitzer and Williams (2001): mild depression ≥ 5, moderate depression ≥ 10, 
moderately severe depression ≥ 15, severe depression ≥ 20. The mean level of baseline 
depression severity in this sample was PHQ-9 = 16.32. We did not have a PTSD-specific 
outcome measure available in this sample, however the PHQ-9 has been shown to be strongly 
associated (r = 0.59) with PTSD symptoms (Gerrity, Corson, & Dobcha, 2007), and therefore 
using it as a primary outcome could be justified. The PHQ-9 has also been extensively 
validated in primary care populations (Kroenke, Spitzer, Williams, & Löwe, 2010; Kroenke 
et al., 2001). 
Generalized Anxiety Disorder 7 (GAD-7). The GAD-7 is a seven-item measure 
developed to screen for anxiety disorders (Spitzer, Kroenke, Williams, & Löwe, 2006). Each 
item is also rated on a 0 to 3 scale, yielding a total anxiety severity score between 0 and 21. In 
the following, the instrument served as potential predictor variable.  
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Work and Social Adjustment Scale (WSAS). Functional impairment was assessed 
using the WSAS (Mundt, Mark, Shear, & Griest, 2002). The WSAS measures the extent to 
which mental health problems impair daily functioning across five domains (work, home 
chores, social leisure, private leisure, and relationships). The internal consistency of the 
WSAS has been found to range from α = .70 to α = .94 with a test-retest reliability of r = .73 
(Mundt et al., 2002). Initial WSAS scores were included in the process of identifying 
treatment-specific predictors. 
Data Analysis Strategy  
Missing data. To address missing data, including missing outcome assessments, we 
implemented a non-parametric missing value imputation procedure using random forests with 
the R package missForest (Stekhoven & Bühlmann, 2012; Stekhoven, 2013). Imputation via 
missForest has been shown to yield a lower imputation error than other common imputation 
approaches (Waljee et al., 2013). Table 1 gives an overview of missing values in the analysis 
sample. A good performance of missForest for continuous variables is assessed with the 
normalized root mean squared error (NRMSE) and for categorical variables using a 
proportion of falsely classified entries (PFC) close to zero (Stekhoven & Bühlmann, 2012). 
Imputation was successful with a NRMSE of 0.30 and a PFC of 0.12. All further depictions 
and analyses are based on the imputed dataset. 
 Propensity Score Matching. Since the present data stem from a naturalistic 
treatment context, we had to adjust for confounding by indication. Therefore, we 
implemented propensity score matching (PSM; Rosenbaum & Rubin, 1983; Lutz, Schiefele, 
Wucherpfennig, Rubel, & Stulz, 2016). PSM can be used to match or to equate groups based 
on comparable baseline characteristics (West et al., 2014). We performed PSM in R based on 
the MatchIT package (Ho et al., 2011) using optimal matching. Optimal matching finds the 
matched samples with the smallest average absolute distance across all the matched pairs 
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based on all available baseline characteristics. The process was iterated until all optimal 
matches between the EMDR sample and the Tf-CBT sample were found. For this study, we 
implemented the standardized mean difference (SMD) technique, a widely used method to 
check covariate balance between samples (e.g., Guo & Fraser, 2014). The SMD method is 
similar to Cohen`s d and allows the comparison of differences in matched and unmatched 
conditions for each covariate (with the SD of the unmatched condition being used as the 
denominator). A SMD < .25 indicates acceptable match between samples on the respective 
covariates (Rubin, 2001). For further analyses, all predictors were centered within the 
respective treatment condition: continuous variables were grand mean-centered whereas 
dichotomous variables were dummy coded with values set to –0.5 and 0.5 (Kraemer & 
Blasey, 2004). 
Selection of variables via a genetic algorithm. Traditional methods for model 
selection are based on null hypothesis testing (e.g., Anderson, 2007; Anderson & Burnham, 
2002). This often includes a stepwise procedure where the researcher fits the full model and 
looks for terms that are not statistically significant, i.e., whose removal does not significantly 
reduce the fit of the model. The procedure can be repeated until all effects in the formula are 
found significant. This approach is often called ‘backward elimination’. A similar strategy is 
to start from the simplest model and to sequentially add the most significant effects (a 
‘forward selection’ approach). Hence, for each step a significance test is needed to determine 
whether the removal or addition of a given term is useful. Since the number of tests is 
typically high, this poses the problem of choosing a relevant significance level (Harrell, 
2001).  
We used a genetic algorithm (GA) for model selection, which overcomes the above 
described problems of traditional methods and is considered to be robust and efficient 
(Calcagno & Mazancourt, 2010). The basic idea of the algorithm is that there is not one 
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perfect model, but a set of candidate models that are satisfactory, which results in a set of 
variables that are important for further analyses. The importance of a predictor variable is 
calculated by summing up the weights for the models in which the variable appears. We used 
an 80% importance threshold to differentiate between important and not so important 
variables (Calcagno & Mazancourt, 2010).  
In this paper we implemented GA in R based on glmulti, a package for automated 
model selection (Calcagno, 2013). The package produces model formulas, which are passed 
through a fitting function. In our case, this fitting function is a linear regression model with 
treatment outcome (PHQ-9 final score) as dependent variable. We included initial symptom 
measures (PHQ-9, WSAS, GAD-7) as well as other available variables (comorbid long-term 
medical condition, disability, antidepressant medication, gender, age, employment status) as 
candidate predictors in the model selection process. Medication and employment status were 
included in the analysis as binary variables. The medication variable included cases that were 
“prescribed antidepressant medication” (52.17%) and those who were “prescribed but not 
taking antidepressant medication” (1.34%) into a single category (coded 0.5), with “no 
prescribed medication” (46.49%) as the reference category (coded -0.5). Employment status 
was collapsed merging “employed” (50%) and “student” (3.47%) into a single category 
(coded 0.5), versus “unemployed” (“unemployed” (2.43%), “longterm sick” (11.46%) and 
“other” (32.64%)) which was the reference category (coded -0.5). See Table 1 for a more 
detailed description concerning treatment groups. Since interactions of variables with 
treatment conditions require large sample sizes (Calcagno & Mazancourt, 2010), we 
computed separate models for each treatment (Kessler et al., 2017).  
Personalized Advantage Index (PAI). We used a leave-one-out approach (Efron & 
Gong, 1983; DeRubeis et al., 2014), in which regression models were estimated according to 
the sample size of each treatment condition (Tf-CBT N = 150 & EMDR N = 75). Each of the 
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models excluded the target patient for whom the PAI prediction was estimated to avoid 
overfitting. For each patient, two separate predictions were made, one based on the Tf-CBT 
(N = 150) treatment-specific predictors established in the preceding step and one for EMDR 
(N = 75). Since patients had received one of the two treatments, one prediction represented 
the patient’s factual (predicted score for the treatment the patient actually received) prediction 
and the other represented the patient’s counterfactual (predicted score for the treatment the 
patient did not receive) treatment prediction.  
In a next step, the aim was to test the within-sample utility of the model for enhancing 
the treatment outcome through treatment assignment. First, we examined the true error as the 
average of the absolute difference between the observed scores and factual predictions. 
Second, we examined the observed change scores of the patients. For that we compared the 
predictions from the two regression models for every patient and we refer to the treatment 
condition predicted to have a greater benefit as the optimal treatment, whereas the other is 
referred to as a sub-optimal treatment. We then classified patients accordingly as having 
received the optimal or sub-optimal treatment and compared the rates of clinically significant 
improvement achieved in both groups between pre- and post-assessments (difference of 6 
points on the PHQ-9; Richards & Borglin, 2011). To aid interpretation from a clinical 
perspective, we calculated the number-needed-to-treat (NNT) using the formulae provided by 
Kraemer and Kupfer (2006). Finally, we calculated for each patient the predicted absolute 
difference in outcome between receiving their optimal versus sub-optimal treatment. 
Following DeRubeis et al. (2014), we referred to the index of the predicted advantage as the 
Personalized Advantage Index (PAI).  
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Results 
Comparison of Tf-CBT and EMDR  
Comparing the effect sizes (Cohen’s d) between treatment conditions, there were no 
significant differences between Tf-CBT (PHQ-9: d = 0.81, 95% CI [0.63,1.00]) and EMDR 
(PHQ-9: d = 0.89, 95% CI [0.55, 1.22]) concerning average treatment effectiveness (see 
Table 2).  
Independent-samples t tests and χ2 tests were calculated to further compare baseline 
variables (see Table 1) between the two treatment conditions. In summary, the two 
naturalistic samples differed systematically in a number of the investigated baseline variables, 
as was to be expected in observational data. Consequently, PSM was necessary before 
selecting variables for model building. 
Propensity Score Matching 
 The matching process via optimal matching (Ho et al., 2011) with all baseline 
variables resulted in a subsample of 150 patients of the Tf-CBT sample while all EMDR (N = 
75) cases were included (see Table 1). After applying PSM, all baseline variables were 
sufficiently well balanced, as none of the SMD scores exceeded .25. The sample selection 
process is presented in a flow chart in Figure 1. For correlations of baseline variables, see 
Appendix Table A1.  
Separate variable selection for Tf-CBT and EMDR 
Relevant Variables for Tf-CBT. The genetic algorithm selected four variables for 
Tf-CBT (see Table 3 and Table 4). Higher functional impairment (WSAS) at the beginning of 
therapy significantly predicted higher PHQ-9 end scores (B = 0.24, t(147) = 4.30, p < 0.001) 
whereas female patients showed better therapy outcomes (B = -2.09, t(147) = -1.93, p = 0.06). 
Furthermore, being employed and being older led to significantly better therapy outcomes (B 
= -4.99, t(147) = -4.21, p = 0.001; B = -0.10, t(147) = -2.51, p = 0.01) 
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Relevant Variables for EMDR. For EMDR, the variable selection process identified 
two variables (see Table 3). First, higher PHQ-9 scores at the beginning of treatment 
significantly predicted higher end scores in the same instrument (B = 0.44, t(72) = 2.77, p < 
0.001). Furthermore, patients who were prescribed antidepressants tended to have poorer 
treatment outcomes compared to patients that were not prescribed medications (B = 4.40, 
t(72) = 3.77, p < 0.01; see Table 4).  
Personalized Advantage Index (PAI) 
The prediction of an individual's final PHQ-9 score was developed separately for each 
treatment condition based on treatment-specific predictors described above. The true error of 
the PHQ-9 post-treatment score predictions was 5.07, representing the average absolute 
difference between the predicted and actual scores across the 225 patients. The true error for 
the EMDR model (N = 75) and the Tf-CBT model (N = 150) was 5.37 and 4.92, respectively. 
In Figure 2, we present the frequency of predicted PHQ-9 post-treatment scores in both the 
optimal and sub-optimal treatment, a lower PHQ-9 score representing better therapy 
outcome. Patients who were classified as having received their optimal treatment had an 
observed mean PHQ-9 post score of 7.86 (SD = 6.77; n = 124) which would be classified as 
mild depression (Kroenke, Spitzer, & Williams, 2001). Patients who received their predicted 
sub-optimal treatment had a PHQ-9 post-treatment score of 10.89 (SD = 8.17; n = 101) which 
can be classified within the range of moderate depression. The standardized difference in 
observed PHQ-9 post-treatment scores between patients who received their predicted optimal 
treatment and patients who received their sub-optimal treatment corresponds to Cohen’s d = 
0.40 (95% CI [0.13, 0.67]). This finding can be translated into a NNT = 4.49, meaning that it 
is necessary to treat between four and five patients in their predicted optimal treatment to 
attain one additional case with reliable improvement, by comparison to the sub-optimal 
treatment. 
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To further test the utility of our approach, we compared the rates of reliable 
improvement between patients who had their optimal or their sub-optimal treatment based on 
the treatment-specific predictors. Table 5 shows that sixty-three percent (n = 78) of the 
patients receiving their optimal treatment (n = 124) had a reliable improvement after 
treatment, while in the group of patients receiving their sub-optimal treatment this was only 
true for 33.66% (n = 34). In total the model prediction was true for 64.44% (n = 145) percent 
of the total sample (n = 225). The presented frequencies in Table 5 were significantly 
different, χ2(1, n = 225) = 19.54, p < .001.  
Based on the predictions, the PAI for each individual patient was calculated by 
subtracting the predicted outcomes for the model-determined optimal treatment from the sub-
optimal treatment. The average PAI was 2.49 (SD = 1.92, range = 0.01 – 9.34), representing 
an expected average of 2.49 point difference in PHQ-9 post-treatment scores between the 
predicted optimal treatment (predicted M = 7.97, SD = 3.47, range = 0.62 – 14.56) versus the 
sub-optimal (predicted M = 10.47, SD = 3.68, range = 2.36 – 18.07) treatment. The predicted 
benefit of treatment selection is displayed in Figure 3 based on the frequencies of PAI scores. 
Note that the PAI can be as low as zero, which occurs when the same outcome is predicted 
for both treatments. For 32 patients (14.22%) the PAI was close to zero (PAI <= 0.5) 
meaning that for those patients there was no predicted difference between the two treatment 
conditions. Helping to classify the importance of the difference between predicted optimal 
and sub-optimal treatment, the PAI was further inspected regarding its standard deviation 
(SD; see Figure 3). Hence, a PAI of 0.96 corresponds to half a SD. In our sample, 171 
patients (76%) had a PAI of this size or larger. Furthermore, 55.56% (n = 125) of the patients 
had a PAI that corresponds to one SD. From those, 63 patients (49.6%) did not receive their 
model predicted optimal treatment and could have benefited from an algorithm-based 
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treatment assignment. A PAI equal or higher than two SDs was true for 22.67% (n = 51) of 
the patients of the sample.  
Discussion 
This is the first study using the PAI approach in a naturalistic PTSD sample treated by 
either Tf-CBT or EMDR. We explored how patients’ pretreatment characteristics may guide 
optimal treatment assignment to enhance therapy outcome for PTSD patients in the context of 
otherwise highly effective treatments.  
Main findings 
In the matched naturalistic treatment conditions, we identified treatment-specific 
outcome predictors. For Tf-CBT, functional impairment, age, gender and employment status 
were significant predictors. For EMDR initial impairment as well as prescribed 
antidepressant medications were significant variables for outcome prediction.  
As expected, outcomes for patients who received their model determined optimal 
treatment were better than those of patients who received their sub-optimal treatment. 
Patients in their model-predicted optimal treatment finished treatment with PHQ-9 scores in 
the range of mild depression, whereas observed scores for those who received their sub-
optimal treatment were still in the range of moderate depression. Although the difference in 
absolute terms between those two groups could be classified as small (3.03 points difference 
in PHQ-9 units) it corresponds to a NNT close to four. Bearing in mind that in the present 
study two highly effective treatments for PTSD were compared with each other, a NNT of 
four is an impressive effect size difference. In comparison, a meta-analysis which focused on 
the relative efficacy of psychotherapies for PTSD reported an effect size of 0.16 which 
translates into NNT = 12 (Benish, Imel, & Wampold, 2008). Concerning the prediction 
models, 56% (n = 125) of the sample had a PAI equal or higher than one SD. From those, 
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50% (n = 63) did not receive their model predicted optimal treatment and could have 
benefited from an algorithm-based treatment assignment. 
Our results are consistent with existing literature where the PAI predicted a 
meaningful advantage for ~60% of cases receiving their optimal treatment (DeRubeis et al., 
2014; Huibers et al., 2015). Despite these similarities, there are important differences 
concerning diagnoses, outcome measures and definitions of clinically important change. 
Nevertheless, as in previous studies, we found that the PAI approach is promising enough in 
retrospective samples to justify its application prospectively in applied research studies.  
It is still unclear if it is better to build treatment selection models by searching for 
moderators that are interactions of predictors with treatment in the whole sample (prescriptive 
models) or by developing separate prognostic models within each treatment condition. Until 
now, most of the PAI studies used a prescriptive approach (for example DeRubeis et al. 2014; 
Huibers et al., 2015). Others suggested using prognostic models in large observational 
treatment studies to answer questions concerning personalized predictions (e.g., Delgadillo et 
al., 2017; Kessler et al., 2017). Up to this point, there is no empirical evidence to guide us on 
the relative strengths, weaknesses or differences between these modelling strategies. We 
decided to use a prognostic approach since finding interactions in small samples has low 
statistical power. Nevertheless, future research needs to address this empirical question.  
Strengths and limitations 
The current study is the first to apply the PAI approach in a naturalistic PTSD sample. 
So far, research investigated the PAI approach focusing solely on depression RCT samples. 
RCT samples are highly selective since only patients can be included who agree to be treated 
with each of the treatments investigated. The present study used a patient preference design 
where patients can choose between two available treatments within the context of routine 
care. As a consequence, in a RCT sample model selection is compared to randomization 
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which is far from being an approach used in routine care. In contrast to that, due to the 
present study design, model prediction is compared to patient preference which has more 
meaning for clinical practice. That is, our results show that with a machine learning based 
approach for treatment selection better outcomes can be achieved than with a selection based 
on patient preferences. Of course, this assumes that patients who have a preference for a 
certain treatment can be convinced by the data to select a different treatment than their 
preferred one if this promises better outcomes for them. However, even if patients agree to 
undergo a treatment that is not their first choice, it is unclear whether this preference per se 
might influence treatment outcomes.  Future applications of the PAI in RCTs and naturalistic 
contexts explicitly need to take patient preferences into account in order to get a better 
understanding of the role of this potentially important variable.  
Apart from this, the use of retrospective data to determine the potential utility of the 
PAI still raises some questions about the viability, acceptability, and potential effects of using 
this strategy to prospectively assign patients to treatments. Nonetheless, a genetic algorithm 
as well as a leave-one-out approach was implemented to enhance the probability that the 
identified predictor variables will be replicated in other samples. Furthermore, we have 
demonstrated and replicated the usefulness of the PAI approach, which justifies the effort to 
conduct prospective studies. To our knowledge, there is only one project that is applying 
prospective personalized treatment recommendations in an outpatient clinic (Lutz, 
Zimmermann, Müller, Deisenhofer, & Rubel, 2017). Instead of the PAI, personalized 
predictions are based on a nearest neighbor approach (NN). In our view, this is the first step 
to bring personalized treatments finally within reach (Cuijpers & Christensen, 2017).  
A further limitation concerns the relatively small sample size in which these models 
were evaluated. There is a potential risk of overconfidence due to the fact that variable 
selection was performed on the full sample. Unfortunately, due to the sample size we could 
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not test the validation of our analyses in an external validation sample. There is a clear need 
for replications in bigger samples that allow external validation.  
Another limitation refers to the main outcome measure PHQ-9 which is an instrument 
to assess depressive symptoms, but which in English IAPT services is one of the few 
mandatory instruments in routine data collections. Consequently, our results may not 
generalize to PTSD symptoms assessed with disorder-specific measures. Nevertheless, we 
still found meaningful differences between optimal and sub-optimal treatments and they 
therefore encourage future investigations using PTSD-specific instruments (Brewin, 2005). 
One possible explanation of our finding is that depression is one of the most common 
comorbid diagnoses in PTSD (Bradley et al., 2005).  
PSM has its advantages and limits, and this study is no exception (Shadish, 2013). 
Although the method is able to account for observed potential confounders, there is still the 
possibility that unobserved variables might have had an influence on treatments, treatment 
selection, or therapy outcome. Nevertheless, we think that complete elimination of bias is 
unrealistic and the advantage of implementing the PAI in routine care data outweighs the 
potential shortcomings of the matching method.   
Conclusions 
Acknowledging the above limitations, this article adds to the growing body of 
research on personalized treatments in psychotherapy research. Results suggest that it is 
possible to enhance individual treatment outcomes in assigning PTSD patients to their 
optimal treatment. This kind of study promotes the development of meaningful decision trees, 
which will result in supported clinical decision-making (see: Lutz, de Jong, & Rubel, 2015). 
In the future, PAIs could be integrated in the diagnostic process at the beginning of 
psychotherapy to find the optimal treatment for a patient in advance. Matching patients to 
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their model-determined optimal treatment could potentially further enhance treatment 
outcomes.   
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Figure 1. Flow chart of sample preparation and selection. IAPT = Improving Access to 
Psychological Therapies; PTSD = post-traumatic stress disorder; crossover cases = patients 
treated by therapists that offered both treatments; Tf-CBT = trauma-focused cognitive 
behavioral therapy; EMDR = eye movement desensitization and reprocessing; PSM = 
Propensity Score Matching. 
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Figure 2. Distribution of predicted PHQ-9 post scores in the optimal and sub-optimal treatment. 
Optimal = treatment condition with a predicted benefit for the individual patient; Sub-optimal 
= treatment condition which is predicted as being less effective for the individual patient.  
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Figure 3. Distribution of PAI scores. PAI = Personalized advantage index (Magnitude of the 
predicted difference between optimal and sub-optimal treatment); SD = Standard Deviation; ½ 
SD = 0.96; 1 SD = 1.92; 2 SD = 3.85. 
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Table 1. Sample baseline characteristics (after imputation)  
Note. Tf-CBT = trauma-focused cognitive behavioral therapy; EMDR = eye-movement 
desensitization and reprocessing; PHQ-9 = patient health questionnaire; GAD-7 = 
Generalized Anxiety Disorder; WSAS = work and social adjustment scale; LTC = lifelong 
medical condition (e.g., diabetes, heart disease, chronic pain, arthritis, etc.).  
A Other = voluntary work, homemaker, carer, or retired  
B Medication = Antidepressants 
 
  
 Tf-CBT 
(N = 242) 
Tf-CBT 
(N = 150) 
EMDR 
(N = 75) 
Missing data 
(before 
imputation)  
 Mean (SD) or % Mean (SD) or % Mean (SD) or %  (%) 
PHQ-9pre  17.49 (6.42) 15.49 (6.91) 15.22 (6.92)  5.40 
PHQ-9post  11.46 (8.11) 9.42 (7.59) 8.81 (7.55)  0.30 
GAD-7pre 15.37 (5.06) 14.13 (5.67) 14.11 (5.71)  5.40 
WSASpre 22.11 (9.53) 21.11 (10.02) 21.18 (10.85) 15.10 
Gender (female) 44.63 56.67 60.00 0 
Age 38.33 (12.20) 39.39 (12.40) 41.85 (12.52) 0 
LTC 27.69 26.00 25.33 0 
Disability 68.60 50.67 42.67 0 
Employment 
- Employed 
- Student 
- Unemployed  
- Longterm sick 
- OtherA 
 
47.93 
1.65 
3.31 
10.33 
36.78 
 
52.00 
3.33 
2.67 
12.00 
30.00 
 
46.67 
 2.67 
 4.00 
16.00 
30.67 
 
 9.10 
MedicationB 
- Prescribed  
- Prescribed not 
taking 
- Not prescribed 
 
54.13 
0.41 
45.45 
 
50.67 
0.67 
48.67 
 
46.67 
 4.00 
49.33 
 
 
 5.70 
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Table 2. Treatment outcome in different samples after imputing and matching  
Measure Sample dA 
Confidence Interval 
Lower Limit Upper Limit 
PHQ-9 
IAPT (N = 225) 0.84 0.64 1.03 
Tf-CBT (n = 150) 0.82 0.58 1.05 
EMDR (n = 75) 0.89 0.55 1.22 
GAD-7 
IAPT (N = 225) 0.90 0.7 1.09 
Tf-CBT (n = 150) 0.91 0.67 1.15 
EMDR (n = 75) 0.86 0.53 1.20 
WSAS 
IAPT (N = 225) 0.73 0.54 1.92 
Tf-CBT (n = 150) 0.67 0.43 0.90 
EMDR (n = 75) 0.85 0.51 1.18 
Note. Tf-CBT = trauma-focused cognitive behavioral therapy; EMDR = eye-movement 
desensitization and reprocessing; PHQ-9 = patient health questionnaire 9; GAD-7 = 
Generalized Anxiety Disorder 7; WSAS = work and social adjustment scale.  
A Effect size d was computed using the pooled standard deviation of pre and post treatment 
scores. 
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Table 3. Importance values for predictor variables for Tf-CBT and EMDR. 
 Importance 
Tf-CBT (N = 150) 
Importance 
EMDR (N = 75) 
PHQ-9pre 0.60 0.95 
GAD-7pre 0.40 0.30 
WSASpre 0.81 0.28 
Gender (female) 0.82 0.51 
Age 0.91 0.30 
LTC 0.30 0.53 
Disability 0.27 0.28 
Employment 1.00 0.28 
Medication 0.34 0.95 
Note. Importance = sum of model weights. An importance of 0.80 is used as cutoff to 
differentiate between important and not important variables. Tf-CBT = trauma-focused 
cognitive behavioral therapy; EMDR = eye-movement desensitization and reprocessing; 
PHQ-9 = patient health questionnaire; GAD-7 = Generalized Anxiety Disorder; WSAS = 
work and social adjustment scale; LTC = lifelong medical condition (e.g., diabetes, heart 
disease, chronic pain, arthritis, etc.); Medication = “prescribed antidepressant medication” 
coded as 0.5 with “no prescribed antidepressant medication” as reference category; Employed 
= “employed” coded as 0.5 with “unemployed” as reference category. WSAS = work and 
social adjustment scale; Gender = female coded as 0.5. 
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Table 4. Separate regression models for EMDR and Tf-CBT with treatment specific 
predictors and PHQ-9 as outcome variable. 
  B SE B β t 
EMDR 
(N = 75) 
Intercept   8.78 0.71   0.00 12.42*** 
PHQ-9   0.44 0.12   0.40   2.77** 
Medication   4.40 1.59   0.29   3.77*** 
Tf-CBT 
(N = 150) 
Intercept   9.83 0.50   0.00 19.41*** 
WSAS   0.24 0.06   0.32   4.30*** 
Employed - 4.99 1.19 - 0.33 - 4.21*** 
Age - 0.10 0.04 - 0.17 - 2.51* 
Gender - 2.09 1.08 - 0.14 - 1.93 
Note. Tf-CBT = trauma-focused cognitive behavioral therapy; EMDR = eye-movement 
desensitization and reprocessing; PHQ-9 = Patient Health Questionnaire; Medication = 
“prescribed antidepressant medication” coded as 0.5 with “no prescribed antidepressant 
medication” as reference category; Employed = “employed” coded as 0.5 with “unemployed” 
as reference category. WSAS = work and social adjustment scale; Gender = female coded as 
0.5. 
A N = 75. B N = 150. 
*** p < 0.001, * p < 0.05. 
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Table 5. Testing the utility of the PAI approach with regard to observed scores and reliable 
change 
 
 Optimal 
n (%) 
Sub-Optimal 
n (%) 
Reliable change 
yes 78 (62.90) 34 (33.66) 
no 46 (37.10) 67 (66.34) 
Note. PAI = Personalized advantage index; Reliable change index >= 6 for the PHQ-9 
(Richards & Borglin, 2011); Optimal = treatment condition with a predicted benefit for the 
individual patient; Sub-optimal = treatment condition which is predicted as being less 
effective for the individual patient.  
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Appendix 
Table A1. Correlations of baseline variables 
Note. PHQ-9 = patient health questionnaire; GAD-7 = Generalized Anxiety Disorder; WSAS 
= work and social adjustment scale; LTC = lifelong medical condition (e.g., diabetes, heart 
disease, chronic pain, arthritis, etc.); Medication = “prescribed antidepressant medication” 
coded as 0.5 with “no prescribed antidepressant medication” as reference category; Employed 
= “employed” coded as 0.5 with “unemployed” as reference category; Gender = female coded 
as 0.5. 
*** p < 0.001, * p < 0.05. 
 
Variables 1 2 3 4 5 6 7 8 9 
1. PHQ-9pre -         
2. GAD-7pre  0.83*** -        
3. WSASpre  0.73***  0.66*** -       
4. Age  0.07  0.06  0.08 -      
5. Gender -0.02 -0.01 -0.08 -0.09 -     
6. LTC  0.00  0.05  0.10  0.04 -0.03 -    
7. Disability -0.01  0.04  0.03  0.12 -0.03 -0.02 -   
8. Employment -0.40*** -0.40*** -0.41*** -0.11  0.28*** -0.10 -0.12 -  
9. Medication  0.44***  0.36***  0.46***  0.16* -0 08  0.01 -0.09 -0.24*** - 
